TY - JOUR T1 - The potential impact of the COVID-19 pandemic on the tuberculosis epidemic – a modelling analysis JF - medRxiv DO - 10.1101/2020.05.16.20104075 SP - 2020.05.16.20104075 AU - Lucia Cilloni AU - Han Fu AU - Juan F Vesga AU - David Dowdy AU - Carel Pretorius AU - Sevim Ahmedov AU - Sreenivas A.Nair AU - Andrei Mosneaga AU - Enos Masini AU - Suvanand Sahu AU - Nimalan Arinaminpathy Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/20/2020.05.16.20104075.abstract N2 - Background Routine services for tuberculosis (TB) are being disrupted by stringent lockdowns against the novel SARS-CoV-2 virus. We sought to estimate the potential long-term epidemiological impact of such disruptions on TB burden in high-burden countries, and how this negative impact could be mitigated.Methods We adapted mathematical models of TB transmission in three high-burden countries (India, Kenya and Ukraine) to incorporate lockdown-associated disruptions in the TB care cascade. The anticipated level of disruption reflected consensus from a rapid expert consultation. We modelled the impact of these disruptions on TB incidence and mortality over the next five years, and also considered potential interventions to curtail this impact.Results Even temporary disruptions can cause long-term increases in TB incidence and mortality. We estimated that a 3-month lockdown, followed by 10 months to restore normal TB services, would cause, over the next 5 years, an additional 1.65 million TB cases (Crl 1.49– 1.85) and 438,000 TB deaths (CrI 403 – 483 thousand) in India, 41,400 (28,900–62,200) TB cases and 14,800 deaths (10.5 – 19.2 thousand) in Kenya, and 7,960 (6,250 – 9,880) cases and 2,050 deaths (1,610 – 2,360) in Ukraine. However, any such negative impacts could be averted through supplementary “catch-up” TB case detection and treatment, once restrictions are eased.Interpretation Lockdown-related disruptions can cause long-lasting increases in TB burden, but these negative effects can be mitigated with targeted interventions implemented rapidly once lockdowns are lifted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUSAID, Stop TB PartnershipAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are contained within the manuscript and supporting information ER -